- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
Big Pharma: Where's the Risk Management?
-
Generic Players Continue to Impress in H1
-
Pharmaceutical Dollar Rationing by Results
-
Smaller Pharma Wins the 'Most Valuable' Race
-
Lilly's Free Compound Screening Will Draw Many Takers
-
Yields of S&P's Dividend Aristocrats
-
How Bad Is Sanofi's Safety Scare?
-
81 Dividend Growers to Consider
-
ADA Meeting 2009: Novel Diabetes Therapies Presented
-
51 Option Ideas for Bears
-
China Biotech in Review: New Developments
-
Eli Lilly: Dividend Stock Analysis
-
Biotech Set to Dominate Drug Industry Growth
-
Seven Laggard Biotech Trades
-
For Lilly, Challenges Remain
-
Lilly Offers Free Compound Testing in Collaboration with Lab Researchers
-
Alimta: The 'Winner' of ASCO 2009
-
Lilly's Alzheimer Drug Lawsuits Just Got Messier
-
Canadian Fund Portfolio Update
-
Wall Street Breakfast: Must-Know News
-
Preview from Europe: Stocks Snooze
-
Galleon Bets Heavily on the S&P 500
-
Amylin Update Post ADA Meeting
-
Market Recovery Means Learning from Our Mistakes
-
FDA Calendar Updates: ABT, AFFY, AZN, LLY, MELA, PFE, SOMX, VPHM
-
The Imperatives of Healthcare Reform
-
FDA, Clinical Trial Updates: MAP Pharma, Cytokinetics, Hemispherx Post Big Gains
-
Why I'm Adding to My Position in Ely Lilly
-
FDA, Clinical Trial Updates: Genzyme, Human Genome Sciences, Eli Lilly, NeurogesX
-
Is Mylan Short Base Rising over Uncertainties in Healthcare?
-
S&P Dividend Aristocrats Getting Through the Credit Crisis
-
Broader Market Outperforming Dividend Aristocrats
-
Big Pharma Maintains Illusion of Innovation
-
Why Is Eli Lilly's CEO on the Media Offensive?
-
Eli Lilly CEO on Nationalized Health Insurance: Cost Effectiveness Stifles Innovation
-
Cypress Bioscience: Investing in Pain
-
AstroZeneca: Brilinta News Not a Panacea
-
Amylin: Icahn's Proxy Damning for Management
-
Vanda Pharmaceuticals: Tomorrow's Headline Stock
-
Who Will Win the Amylin Battle?
-
WuXi Wins Lilly Global Supplier Award